Divi's Laboratories Limited has officially notified stock exchanges about an upcoming board meeting scheduled to review and approve its third-quarter financial performance for fiscal year 2026. Additionally, the pharmaceutical company will host an earnings conference call on the same day to discuss the financial results with stakeholders.

Board Meeting and Earnings Call Schedule

The company has provided comprehensive details regarding both the board meeting and subsequent earnings conference call:

Conference Call Access Information

Divi's Laboratories has arranged multiple options for stakeholders to participate in the earnings conference call. The company offers two primary methods for joining the discussion:

Express Join Option: Participants can pre-register using DiamondPass™ to join without waiting for operator assistance through the dedicated registration link.

Dial-In Numbers: Universal access is available through multiple phone numbers including +91 22 6280 1526 and +91 22 7115 8341. Participants are advised to dial approximately five minutes before the scheduled start time.

Regulatory Compliance and Trading Window

The board meeting announcement follows strict adherence to SEBI regulations, specifically Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The earnings conference call notification also complies with the same regulatory framework.

The company has implemented a trading window closure as part of its insider trading prevention measures:

Investor Relations and Additional Resources

The company has designated specific contact channels for investor inquiries. Investor relations can be reached through mobile number +91 91542 18881 or phone number +91 40 66966352. Following the conference call, a complete transcript will be made available on the company's official website at www.divislabs.com .

Stock Exchange Communication

Divi's Laboratories has formally communicated these developments to both the National Stock Exchange of India Limited and BSE Limited. The company trades under the symbol DIVISLAB on NSE and carries scrip code 532488 on BSE. The notifications were signed by M. Satish Choudhury, Company Secretary & Compliance Officer, ensuring proper authorization and compliance with corporate governance standards.

Divis Laboratories reported robust export performance in December, with shipments reaching $117.00 million, marking a significant 49.00% growth compared to the previous month. This strong performance demonstrates the pharmaceutical company's expanding international market presence and growing global demand for its products.

December Export Performance

The company's December export data reflects substantial momentum in its international business operations. The following table summarizes the key performance metrics:

Market Position Strengthening

The 49.00% month-on-month increase in export shipments indicates strong demand for Divis Laboratories' pharmaceutical products in international markets. This performance suggests the company's continued success in maintaining and expanding its global customer base while effectively meeting international quality and delivery requirements.

The $117.00 million export figure represents a significant milestone for the company's international operations, reflecting both operational efficiency and market competitiveness in the global pharmaceutical sector. This growth trajectory demonstrates the company's ability to capitalize on international opportunities and maintain strong relationships with overseas clients.